Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal.

[1]  G. Lip,et al.  Stroke prevention in atrial fibrillation: Past, present and future , 2017, Thrombosis and Haemostasis.

[2]  D. Singer,et al.  Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation , 2017, Circulation.

[3]  G. Lip,et al.  Adding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation , 2017, Circulation.

[4]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[5]  P. Kirchhof,et al.  [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS]. , 2016, Kardiologia polska.

[6]  E. Antman,et al.  Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. , 2016, JAMA cardiology.

[7]  Matteo Bottai,et al.  Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. , 2016, European heart journal.

[8]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  G. Lip,et al.  Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. , 2016, The American journal of medicine.

[10]  J. Healey,et al.  2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. , 2016, The Canadian journal of cardiology.

[11]  Miguel Mendes,et al.  Dabigatran in real-world atrial fibrillation , 2016, Thrombosis and Haemostasis.

[12]  A. Camm,et al.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation , 2016, Heart.

[13]  D. Lane,et al.  Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.

[14]  Spiros Denaxas,et al.  Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care , 2016, Heart.

[15]  T. Lobban,et al.  Managing reversal of direct oral anticoagulants in emergency situations , 2016, Thrombosis and Haemostasis.

[16]  L. Fauchier,et al.  Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? , 2016, Stroke.

[17]  Peter Brønnum Nielsen,et al.  Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study , 2016, Scientific Reports.

[18]  S. Yusuf,et al.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.

[19]  L. Sposato,et al.  Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. , 2016, Stroke.

[20]  G. Lip,et al.  Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated?: Yes Even 1 Stroke Risk Factor Confers a Real Risk of Stroke , 2016, Circulation.

[21]  G. Lip,et al.  Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores , 2016, Scientific Reports.

[22]  L. Fauchier,et al.  Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. , 2016, Chest.

[23]  G. Lip,et al.  The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation , 2016, Expert review of cardiovascular therapy.

[24]  G. Lip,et al.  Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. , 2015, European heart journal.

[25]  G. Lip,et al.  Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  B. Gorenek,et al.  Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisi , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  Emily C. O'Brien,et al.  The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation , 2015, European heart journal.

[28]  G. Lip,et al.  Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score , 2015, Thrombosis and Haemostasis.

[29]  T. Chao,et al.  The risks of risk scores for stroke risk assessment in atrial fibrillation , 2015, Thrombosis and Haemostasis.

[30]  L. Friberg,et al.  Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. , 2015, Journal of the American College of Cardiology.

[31]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[32]  P. Kirchhof,et al.  Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association , 2014, European heart journal.

[33]  J. Healey,et al.  2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. , 2014, The Canadian journal of cardiology.

[34]  G. Lip,et al.  Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. , 2014, Chest.

[35]  S. Suissa,et al.  Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. , 2014, European heart journal.

[36]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[37]  D. Atar,et al.  High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2013, Circulation.

[38]  S. Hohnloser,et al.  N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). , 2013, Journal of the American College of Cardiology.

[39]  K. Aonuma,et al.  The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation , 2013 .

[40]  C. Granger,et al.  Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.

[41]  G. Lip,et al.  Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS2 and CHA2DS2-VASc Scores in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study , 2013, Circulation. Arrhythmia and electrophysiology.

[42]  G. Lip,et al.  Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation , 2012, Thrombosis and Haemostasis.

[43]  S. Hohnloser,et al.  Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial , 2012, The Lancet.

[44]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[45]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[46]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[47]  Salim Yusuf,et al.  Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial , 2011, Annals of Internal Medicine.

[48]  G. Lip.  The role of aspirin for stroke prevention in atrial fibrillation , 2011, Nature Reviews Cardiology.

[49]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[50]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[51]  R. de Caterina,et al.  Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) , 2008, Stroke.

[52]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[53]  J. Healey,et al.  Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation , 2018 .

[54]  G. Lip,et al.  Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score , 2017, European heart journal. Cardiovascular pharmacotherapy.

[55]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[56]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.